GeneaMed is a fusion of ideas, creativity and years of experience in the treatment and diagnosis of blood proliferative disorders. The company develops innovative therapeutics for severe neoplastic diseases. The latest invention of GeneaMed is the use of dendrimer-based nanoparticles in the targeted treatment of a group of chronic B-cells Lymphoproliferative Disorders (B-CLPDs) with the most common Chronic Lymphocytic Leukemia (CLL).
Our invention won the Golden Medal at the International Invention Fairs "Concours Lepine 2013" in Paris. This year we have won "Master of Innovation 2017" Award at Central European Forum of Biotechnology and Innovative Bioeconomy in Lodz. GeneaMed has three international patent applications. We have obtained positive results on cells from patients and on customer cell lines in vivo. Promising results were also obtained after in vivo trials on animals.
Company Details
- Founded
- -
- Address
- 16/18 Kopcinskiego Str., Suite 904, Łódź,łódzkie 90-232,poland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- geneamed.com
- Keywords
- biotechnology, genetics, molecular biology, pharmacy, hematology, oncology, drug development, pre-clinical studies.
- HQ
- Łódź, łódzkie
Geneamed Questions
Geneamed's website is geneamed.com
Geneamed's LinkedIn profile is https://pl.linkedin.com/company/geneamed
Geneamed's industry is
Pharmaceutical Manufacturing
Geneamed's top competitors are
Forum Farmacji,
Wilco Farma S.r.l.,
Megenzymes,
Probiome,
Cardinal Pharma Joint-Stock Company ( Sa ),
Canpoland S.a.,
Uvera,
Efferta Pharma,
Emergopharm,
Ideas4biology Sp Z. O.o..
Geneamed's categories are Pharmaceutical Manufacturing
Geneamed's founding year is 2015
